Ovarian Cancer

Question 1

Treatment in Stage IA/IB, grade 1 ovarian cancer

Answer 1

surgery alone

Question 2

Treatment in stage IA/IB grade 2-3 or IC ovarian cancer

Answer 2

Surgery + adjuvant chemo of IV taxane + platinum

Question 3

Length of chemo stage IA/IB grade 2-3 or IC ovarian cancer with optimal cytoreduction (

Answer 3

3 cycles

Question 4

Length of chemo stage IA/IB grade 2-3 or IC ovarian cancer with sub-optimal cytoreduction (>1 cm)

Answer 4

6 cycles

Question 5

Criteria for IP therapy for Stage II-IV ovarian cancer

Answer 5

Optimal debulking, good performance status, no Hx of bowel surgery

Question 6

1st line chemo regimen for stage II-IV ovarian cancer

Answer 6

Taxane + platinum IV or IV/IP x6 cycles

Question 7

MOA of bevacizumab

Answer 7

monoclonab Ab against VEGF

Question 8

FDA approval of bevacizumab in ovarian cancer

Answer 8

IN combo with paclitaxel or liposomal doxorubicin or topotecan in platinum resistant ovarian cancer in patients that have received a max of 2 previous regimens

Question 9

Most common SE of bevacizumab

Answer 9

HTN

Question 10

Place in therapy of olaparib in ovarian cancer

Answer 10

BRCA+ mutation and have tried 3 or more lines of therapy

Question 11

MOA of olaparib

Answer 11

PARP inhibitor (causes double strand breaks)

Question 12

Length of time after completion of 1st line chemo to be considered platinum-sensitive and 1st line regimen can be repeated in ovarian cancer

Answer 12

> 6 months

Question 13

antigen that is over-expressed in ovarian epithelial cancers and is a non-specific indicator of pelvic inflammation

Answer 13

CA-125